This problem is exemplified by the number of new approved HER2 directed therapies such as pertuzumab and TDM1, which can augment trastuzumab's effectiveness and/or overcome trastuzumab resistance in HER2 positive breast cancer. Here, ERBB2 is linked to breast carcinoma.